Incyte meets goals in Myelofibrosis trial
December 2010
Incyte Corp. has reported that they have met their goals in their trial of INCB18424 in Myelofibrosis patients. This drug, which treats symptoms of the blood cancer, would be the first drug on the market for a myeloproliferative disorder. In August Incyte indicated that they would also test this drug in Polycythemia Vera patients.
Click here to read the full article











